Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

59.17
+0.03500.06%
Pre-market: 59.15-0.0200-0.03%05:12 EDT
Volume:452.88K
Turnover:26.77M
Market Cap:2.26B
PE:-9.84
High:60.39
Open:59.19
Low:57.72
Close:59.14
52wk High:99.50
52wk Low:30.82
Shares:38.16M
Float Shares:32.89M
Volume Ratio:1.03
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0116
EPS(LYR):-6.0116
ROE:-35.86%
ROA:-22.55%
PB:3.05
PE(LYR):-9.84

Loading ...

Truist Financial Keeps Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
Feb 27

Disc Medicine Q4 EPS $(1.62) Beats $(1.68) Estimate

Benzinga
·
Feb 27

Disc Medicine Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

Disc Medicine (IRON) FY 2025 net loss totals USD 212.2 million

Reuters
·
Feb 26

Disc Medicine FY Basic EPS USD -6.01 VS. Ibes Estimate USD -6.14

THOMSON REUTERS
·
Feb 26

Press Release: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Feb 26

Disc Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 24

Disc Medicine (IRON) Receives a Buy from LifeSci Capital

TIPRANKS
·
Feb 21

Disc Medicine CFO Jean M. Franchi Disposes of Common Shares

Reuters
·
Feb 20

Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares

Reuters
·
Feb 18

Disc Medicine CEO John D. Quisel Reports Sale of Common Shares

Reuters
·
Feb 18

Disc Medicine's Multiple Catalysts Provide Runway Despite Bitopertin Delay, Morgan Stanley Says

MT Newswires Live
·
Feb 18

Wedbush Adjusts Price Target on Disc Medicine to $88 From $110, Maintains Outperform Rating

MT Newswires Live
·
Feb 17

Disc Medicine Inc. i details bitopertin regulatory update and clinical trial progress

Reuters
·
Feb 17

Disc Medicine Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 17

Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod

Reuters
·
Feb 17

Disc Medicine price target lowered to $75 from $120 at Morgan Stanley

TIPRANKS
·
Feb 17

Disc Medicine Exec Says That IF Late-Stage Trial Succeeds, Co Will Seek Approval Through the Traditional Pathway Rather Than the Accelerated Route – Conf Call

THOMSON REUTERS
·
Feb 17

Disc Medicine Exec Says It Expects Late-Stage Data for Bitopertin in Q4 This Year – Conf Call

THOMSON REUTERS
·
Feb 17

Disc Medicine Exec Says the Policy Debate Over Accelerated Approval Has Stretched Across Multiple Administrations, and Recent Decisions Show Regulators Are Taking an "Increasingly Stringent" View of When Such Approvals Are Appropriate – Conf Call

THOMSON REUTERS
·
Feb 17